JP5490346B2 - ４−ヒドロキシタモキシフェンによる乳癌の予防および治療 - Google Patents

４−ヒドロキシタモキシフェンによる乳癌の予防および治療 Download PDF

Info

Publication number
JP5490346B2
JP5490346B2 JP2004570040A JP2004570040A JP5490346B2 JP 5490346 B2 JP5490346 B2 JP 5490346B2 JP 2004570040 A JP2004570040 A JP 2004570040A JP 2004570040 A JP2004570040 A JP 2004570040A JP 5490346 B2 JP5490346 B2 JP 5490346B2
Authority
JP
Japan
Prior art keywords
hydroxy tamoxifen
tamoxifen
breast
breast cancer
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004570040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514967A5 (enExample
JP2006514967A (ja
Inventor
ドミニク サラン−ドルーアン、
ジャック ウェピエール、
フィリップ ルアネ、
Original Assignee
ブザン ヘルスケア ルクセンブルグ エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブザン ヘルスケア ルクセンブルグ エスアーエールエル filed Critical ブザン ヘルスケア ルクセンブルグ エスアーエールエル
Publication of JP2006514967A publication Critical patent/JP2006514967A/ja
Publication of JP2006514967A5 publication Critical patent/JP2006514967A5/ja
Application granted granted Critical
Publication of JP5490346B2 publication Critical patent/JP5490346B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2004570040A 2003-04-01 2003-12-15 ４−ヒドロキシタモキシフェンによる乳癌の予防および治療 Expired - Lifetime JP5490346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
US60/458,963 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2006514967A JP2006514967A (ja) 2006-05-18
JP2006514967A5 JP2006514967A5 (enExample) 2007-02-08
JP5490346B2 true JP5490346B2 (ja) 2014-05-14

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004570040A Expired - Lifetime JP5490346B2 (ja) 2003-04-01 2003-12-15 ４−ヒドロキシタモキシフェンによる乳癌の予防および治療

Country Status (11)

Country Link
US (2) US7704516B2 (enExample)
EP (3) EP1608353B1 (enExample)
JP (1) JP5490346B2 (enExample)
AU (1) AU2003294973B2 (enExample)
CA (1) CA2519980C (enExample)
ES (3) ES2483896T3 (enExample)
IL (1) IL170807A (enExample)
MX (1) MXPA05010597A (enExample)
NO (1) NO333805B1 (enExample)
NZ (1) NZ542499A (enExample)
WO (1) WO2004087123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005227072B2 (en) * 2004-03-22 2010-08-19 Besins Healthcare Luxembourg Sarl Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2582174C (en) * 2004-10-14 2013-01-29 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
CN110044998B (zh) * 2014-05-12 2021-12-14 奎斯特诊断投资公司 通过质谱法定量他莫昔芬及其代谢物
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
JP2026525970A (ja) * 2023-07-19 2026-08-04 アトッサ・セラピューティクス・インコーポレイテッド 抗腫瘍化合物ならびにその使用方法及びその合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (enExample) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
AU2513899A (en) 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ATE290856T1 (de) 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
EP1317921B1 (fr) * 2001-12-07 2009-08-19 Besins International Belgique Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
ES2456957T3 (es) 2014-04-24
WO2004087123A1 (en) 2004-10-14
MXPA05010597A (es) 2006-03-09
AU2003294973A1 (en) 2004-10-25
US8475814B2 (en) 2013-07-02
EP1941871B1 (en) 2014-01-08
NZ542499A (en) 2008-10-31
EP1952810A1 (en) 2008-08-06
HK1086193A1 (en) 2006-09-15
CA2519980A1 (en) 2004-10-14
ES2483896T3 (es) 2014-08-08
IL170807A (en) 2014-08-31
NO333805B1 (no) 2013-09-16
US7704516B2 (en) 2010-04-27
EP1952810B1 (en) 2014-01-08
NO20054526L (no) 2005-09-30
EP1608353A1 (en) 2005-12-28
EP1608353B1 (en) 2014-04-30
ES2456958T3 (es) 2014-04-24
US20090186944A1 (en) 2009-07-23
AU2003294973B2 (en) 2010-05-13
HK1119950A1 (en) 2009-03-20
JP2006514967A (ja) 2006-05-18
US20050031695A1 (en) 2005-02-10
CA2519980C (en) 2012-04-10
EP1941871A1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
US8475814B2 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
JP4684655B2 (ja) ４−ヒドロキシタモキシフェンによる乳房密度低下
JP4938237B2 (ja) ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1579856A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP5072588B2 (ja) ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防
NZ547744A (en) Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
HK1119950B (en) Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1086193B (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1120228A (en) Formulations for the reduction of breast density with 4-hydroxy tamoxifen
HK1130435B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512A1 (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1130435A (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1079453A (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140226

R150 Certificate of patent or registration of utility model

Ref document number: 5490346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term